SpineX, Inc., a clinical stage medtech company announced the groundbreaking results in its first  human study in children with cerebral palsy. The study is published in the esteemed medical journal Nature Communications demonstrating unparalleled functional improvements with its proprietary non-surgical treatment SCiP TM (Spinal Cord Innovation in Pediatrics) in children with Cerebral Palsy (CP).

This study discusses how delivering non-invasive spinal neuromodulation, using SCiP TM , during Physical Therapy improved voluntary sensorimotor function in 16 out of 16 children over a wide range of ages and severities of CP. SpineX was awarded the Breakthrough Device Designation (BDD) from US FDA for SCiP and the proposed treatment of CP.

In addition, SpineX has engaged with FDA to gain alignment on a proposed clinical trial to be conducted in 2023; the results of which are anticipated to lead to FDA clearance of the SCiP TM device for the treatment of CP.

CP is severely debilitating with no current cure. Over 10,000 new cases are diagnosed each year where CP is the result of damage to the developing brain and describes a group of movement disorders that affect a person’s ability to move and maintain balance and posture.

To date there are no methods or medications to prevent or treat CP. Often children with CP are left to be treated with invasive surgeries that attempt to decrease spasticity, a common symptom of the disease.

SCiP TM is a non-invasive spinal electrical neuromodulation device which provides transcutaneous spinal cord neuro-stimulation to potentially treat the underlying neurological dysfunction in pediatric patients with CP.

SCiP TM aims to be the first medical device in the U.S. to treat CP by transforming the brain and spinal cord dysfunctional connectivity into highly functional systems.

“At just three years old and highly affected by CP, our son has shown such exciting progress since he began using SCiP,” said Dana, the mother of a young boy diagnosed with CP who was enrolled in a clinical study sponsored by SpineX. “We’re so grateful that our son was included in the clinical study with SCiP TM as it has opened up a world of possibilities for our son, and we hope others will be able to witness it soon.”

Spinal Neuromodulation is being developed as a platform technology by SpineX and SCiP TM represents their second Breakthrough Device Designation following the SCONE TM device which is in clinical trials for the treatment of Neurogenic Bladder.

https://www.nature.com/articles/s41467-022-33208-w

http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fa-pilot-study-combining&filter=22